Extremely risky in biotech denotes that a drug may not reach approval or that there may not be a way to finance the company. With leronlimab it's not a question of if it will be approved it's just a question of when and whether it will be dozens of approvals or whether it will crack 100. With financing it's not a matter of whether financing can be obtained it's by which route and the cost.